ACCOUNTS RECEIVABLE |
9 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2026 | ||||||||||||||||||||||||||||||||||||||||||||||
| Receivables [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||
| ACCOUNTS RECEIVABLE | 3. ACCOUNTS RECEIVABLE
Accounts receivable consisted of the following:
During the nine months ended June 30, 2026 there was no allowance for doubtful accounts. The receivable balance relates to transactions with Zander Therapeutics, Inc., an entity under common control with the Company through the Company’s CEO. Management has determined that no Allowance for Doubtful Accounts need be recognized due to factors including:
(a) Zander Therapeutics Inc.’s history of loaning money to the Company (b) Instances during the history of the license where Zander satisfied delinquent payments while simultaneously prepaying future periods
|
|||||||||||||||||||||||||||||||||||||||||||||